Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

In vivo studies in NCT with a boronated porphyrin and tumor growth delay as an end point

Conference ·
OSTI ID:10127256
 [1];  [2]; ;  [1]
  1. Brookhaven National Lab., Upton, NY (United States)
  2. California Univ., San Francisco, CA (United States). Dept. of Pharmaceutical Chemistry
The robust carrying capacity of the porphyrin molecule and its propensity for localizing in tumor justified the synthesizing of a porphyrin labeled with boron for use in BNCT. However, problems associated with poor solubility impeded the utility of the molecule. Until BOPP was synthesized porphyrins were promising, but impractical. After in vitro experiments had demonstrated the biological efficacy of BOPP and had confirmed its intracellular localizing ability in vivo studies were carried out using mice. Irradiation of KHJJ murine mammary carcinoma to the TCD{sub 50} in a single fraction was precluded since this whole body dose is lethal. This problem was overcome by the use of radiation. BOPP was administered either as three 0.5 ml injections per day over two days or by continuous i.v. infusion, 2 ml per day over three days for a total dose of about 42 {mu}g {sup 10}B/gbw. Boron-10 distribution in the tumor at the time of irradiation was {approximately}20 {mu}g.
Research Organization:
Brookhaven National Lab., Upton, NY (United States)
Sponsoring Organization:
USDOE, Washington, DC (United States)
DOE Contract Number:
AC02-76CH00016
OSTI ID:
10127256
Report Number(s):
BNL--48323; CONF-9209280--7; ON: DE93006647
Country of Publication:
United States
Language:
English